- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05115825
Pain Management for Head and Neck Cancer Survivors
Survivors of Head and Neck Cancer: Optimizing Pain Management
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Adapt an existing telehealth pain management intervention to target improvement of pain-related physical functioning, mood, substance use, and quality of life in a local sample of veteran head and neck cancer (HNC) survivors.
II. Conduct a pilot of the adapted intervention to examine the feasibility (accrual, adherence, attrition) and acceptability (participant satisfaction) that will form the basis of a well-powered, randomized clinical trial submitted for funding to the National Institutes of Health (NIH), American Cancer Society (ACS), or Veterans Affairs (VA).
OUTLINE:
Patients attend 5 sessions of Mobile Pain Coping Skills Training for 45 minutes each over 8 weeks.
After completion of study, patients are followed up at 2 months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- OHSU Knight Cancer Institute
-
Contact:
- Kara Winchell
- Phone Number: 503-220-8262
- Email: kara.winchell@va.gov
-
Principal Investigator:
- Shannon M. Nugent, Ph.D.
-
Portland, Oregon, United States, 97239
- Recruiting
- Portland VA Medical Center
-
Contact:
- Kara Winchell
- Phone Number: 503-220-8262
- Email: kara.winchell@va.gov
-
Principal Investigator:
- Shannon M. Nugent, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinically confirmed diagnosis of HNC for which the participants have completed curative cancer treatment at the VA hospital or Oregon Health & Science University (OHSU) within the 3-12 months following treatment
- Self-reported current pain of 4 or higher, using the 0-10 Numeric Pain Rating (NRS) (0="no pain" to 10="the worst pain imaginable")
- Self-report of pain 4 or higher on two occasions, more than three weeks apart, since the completion of curative treatment
Exclusion Criteria:
- Enrolled in hospice
- Have substantial hearing or visual difficulties that would impair ability to participate
- Have inadequate cognitive functioning as indicated by medical record review and/or interactions with clinical staff. If needed the investigators can follow up with the St. Louis University Mental State Examination (score of < 22/30) (SLUMS); or
- Have untreated severe psychiatric illness that would impact the ability to consent and participate in the intervention
- Had only surgical treatment for their HNC
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Supportive care (Mobile Pain Coping Skills Training)
Patients attend 5 sessions of Mobile Pain Coping Skills Training for 45 minutes each over 8 weeks.
|
Ancillary studies
Other Names:
Ancillary studies
Attend Mobile Pain Coping Skills Training
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain-interference
Time Frame: Up to 2 months
|
Will be assessed by Brief Pain Inventory.
Will be assessed as 1-4=mild pain; 5-6 moderate pain; 7-10 severe pain.
|
Up to 2 months
|
Depression
Time Frame: Up to 2 months
|
Will be assessed by the Patient Health Questionnaire.
Scores of 5, 10, 15, and 20 represent point scale for mild, moderate, moderately severe and severe depression, respectively.
|
Up to 2 months
|
Pain coping self-efficacy
Time Frame: Up to 2 months
|
Will be assessed by the Chronic Pain Self-Efficacy Scale.
|
Up to 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Substance use
Time Frame: Up to 2 months
|
Will be assessed by the PENN Cravings Questionnaire.
Total score >20 were considered to meet the threshold of craving, 15-20 were considered subthreshold, and <15 were considered non-cravers.
|
Up to 2 months
|
Head and neck cancer related quality of life
Time Frame: Up to 2 months
|
Will be assessed by the University of Michigan Quality of Life Questionnaire.
|
Up to 2 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prescription opioid dose
Time Frame: Up to 2 months
|
Will be assessed via patient report.
|
Up to 2 months
|
Prescription opioid misuse
Time Frame: Up to 2 months
|
Will be assessed using the Chronic Opioid Misuse Measure (COMM).
A score of 9 or greater is suggestive of current problematic drug-related behaviors.
|
Up to 2 months
|
Patient acceptability
Time Frame: Up to 2 months
|
Post-intervention, patients will be asked to rate satisfaction with the program, perception of utility with pain management, using a Likert-scale.
Will inquire about patients' experiences participating in the intervention, perceived burden of participation, perception of the intervention utility, ease of use of the associated technology, and suggestions for improving the intervention.
|
Up to 2 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shannon M Nugent, Ph.D., OHSU Knight Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00019309 (Other Identifier: OHSU Knight Cancer Institute)
- NCI-2021-10801 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Carcinoma
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Ikena OncologyBristol-Myers SquibbWithdrawnHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head Cancer | Neck Cancer | Head Cancer Neck | Neck CarcinomaUnited States
-
Thompson Cancer Survival CenterRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck CarcinomaUnited States
-
University of ChicagoRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Head and Neck Cancer Stage IV | Head and Neck Cancers - ThroatUnited States
-
Washington University School of MedicineCelgene CorporationActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
Memorial Sloan Kettering Cancer CenterRegeneron PharmaceuticalsRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer | Neck Cancer | Head Cancer NeckUnited States
-
University of California, DavisCompletedHead and Neck Cancer | Trauma | Head and Neck Squamous Cell Carcinoma | Head and Neck CarcinomaUnited States
-
University of AlbertaNot yet recruitingHead and Neck Cancer | Head and Neck Neoplasms | Head and Neck Squamous Cell Carcinoma | Head and Neck CarcinomaCanada
-
University of Alabama at BirminghamAventis PharmaceuticalsCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neck NeoplasmsUnited States
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Breast Carcinoma | Head and Neck Carcinoma | Lung Carcinoma | Esophageal Carcinoma | Malignant Digestive System Neoplasm | Malignant Central Nervous System Neoplasm | Genitourinary System CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBreast Carcinoma | Cancer SurvivorUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedFallopian Tube Cancer | Recurrent Endometrial Carcinoma | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Recurrent Ovarian Epithelial Cancer | Stage IV Endometrial Carcinoma | Ovarian... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States